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Abstract
Ovarian clear cell carcinoma (OCCC) is a worst histological subtype than other
ovarian malignant tumor. Heparin-binding epidermal growth factor-like growth
factor (HB-EGF) is a promising target for ovarian cancer therapy. The aims of
this study were to validate the efficacy of HB-EGF–targeted therapy for OCCC
and to identify the transcription factor that contributed to the induction of
HB-EGF by SN38 treatment in OCCC cells. HB-EGF was highly expressed in
OCCC cells, and an increase of HB-EGF was induced by SN38 which had only
antitumor effect among conventional anticancer agents on OCCC. A specific
inhibitor of HB-EGF, a cross-reacting material 197 (CRM197), led to a syner-
gistic increase in the number of apoptotic OCCC cells with the treatment of
SN38. The luciferase assay with 50-deletion promoter constructs identified a
GC-rich element between !125 and !178 (the distal transcription start site was
denoted +1) as a cis-regulatory region, and the treatment of SN38 induced
luciferase activity in this region. An in silico and chromatin immunoprecipita-
tion analysis estimated that SP1 bound to the cis-regulatory region of HB-EGF
in OCCC cells. Real-time PCR and cell viability assays showed that the transfec-
tion of a small interfering RNA targeting SP1 suppressed the expression of
HB-EGF induced by SN38, resulting in the enhanced sensitivity of SN38. Taken
together, these results indicate that induction of HB-EGF expression contrib-
uted to defense mechanism against treatment of SN38 through the transcrip-
tional activity of SP1 in OCCC cells.
Introduction
Ovarian cancer is the most lethal gynecological cancer in
the Western world. Ovarian cancer usually has a poor
prognosis because many cases are diagnosed in advanced
stages. Standard treatment involves surgery, followed by
chemotherapy including platinum derivatives (e.g., cis-
platin [CDDP] or carboplatin) and taxanes (e.g.,
paclitaxel [PTX] or docetaxel). However, the 5-year sur-
vival rate of patients with advanced ovarian cancer has
remained for the past three decades [1]. Ovarian clear cell
carcinoma (OCCC), which is a common histological type
in Japanese, is known to indicate significant drug resis-
tance for conventional anticancer agents, resulting in a
poorer prognosis. Moreover, the occurrence of OCCC,
which links to endometriosis, has rapidly increased
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throughout the world [2]. Therefore, a new strategy for
OCCC therapy has been highly anticipated [2].
Heparin-binding epidermal growth factor-like growth
factor (HB-EGF), which belongs to the EGF family, is
synthesized as an 87 amino acid membrane-anchored gly-
coprotein [3–5]. Cleavage of membrane-anchored
HB-EGF by proteases, called “ectodomain shedding,”
induces the secretion of soluble mature form of HB-EGF
from the cell surface. Through ectodomain shedding, HB-
EGF contributes to several biological processes, such as
wound healing [6], inflammation [7, 8], embryogenesis
[9], and carcinogenesis [10]. In previous reports, we
described that the expression of HB-EGF was higher than
that of other EGFR ligands in the ascites and tissues of
ovarian cancer patients [11, 12]. However, the molecular
mechanism(s) underlying the increase of HB-EGF expres-
sion in ovarian cancer has remained unclear.
There have been several reports that have described
other molecular mechanisms affecting the expression of
HB-EGF. For example, inflammatory cytokines, including
tumor necrosis factor-a and interleukin-1b, directly or
indirectly activated the transcription of HB-EGF [13, 14].
In bladder cancer cells, insulin induces the transcriptional
activation of epiregulin, HB-EGF, and amphiregulin
(AREG), which may be regulated by transcriptional fac-
tors including specific protein 1 (SP1), activator protein-1
(AP-1), and nuclear factor-kappa B (NF-jB) [15]. HB-
EGF was rapidly induced following exposure to a variety
of chemotherapeutic agents, and the chemotherapy-
induced HB-EGF expression was largely dependent on
AP-1 and NF-jB [16]. In addition, transcription factors
including SP1, AP-1, pancreatic and duodenal homeobox-
1 (PDX-1), and myogenic differentiation 1 (MyoD) were
detected as direct regulators of HB-EGF expression [15,
17–19]. However, the molecule(s) directly involved in the
transcript of HB-EGF has remained unknown in human
cancer.
The aim of this study is to assess the association
between HB-EGF expression and the cell viability of
OCCC cells. Additionally, in order to elucidate transcrip-
tional regulation of HB-EGF in OCCC cells, we also per-
formed a screening assay and identified the transcription
factor, SP1, which is responsible for the upregulation of
HB-EGF induced by anticancer agent.
Materials and Methods
Cells and cell culture
Eleven OCCC cell lines (RMG-I, RMG-II, OVISE,
OVTOKO, KK, TU-OC-1, KOC-7C, HAC-2, OVAS,
SMOV-2, ES-2) and 293T cells were used for the studies.
The KK cells were a kind gift from Professor Yoshihiro
Kikuchi, National Defense Medical College, Japan; the
OVAS cells were provided by Professor Hiroshi Minagu-
chi, Yokohama City University, Japan; KOC-7C by Dr.
Toru Sugiyama, Kurume University, Japan; SMOV-2 by
Dr. Tomohiro Iida, St. Marianna University, Japan; and
HAC-2 by Dr. Masato Nishida, Tsukuba University,
Japan. TU-OC-1 cells were derived as described previ-
ously [20]. ES-2 cells were purchased from Summit Phar-
maceuticals International Corporation (Tokyo, Japan).
RMG-I, RMG-II, OVISE, OVTOKO, and 293T cells were
purchased from the Health Science Research Resources
Bank (HSRRB, Osaka, Japan). All OCCC cell lines were
maintained in RPMI-1640 medium (Gibco, Carlsbad,
CA), and 293T cells were maintained in DMEM medium
(Gibco). The culture media were supplemented with 10%
fetal bovine serum (FBS) (ICN Biomedical, Irvine, CA).
Cell viability and apoptosis assay
Paclitaxel (PTX), cisplatin (CDDP), and SN38 (the active
metabolite of irinotecan) were purchased from Sigma-
Aldrich (St. Louis, MO). Recombinant human HB-EGF
(rhHB-EGF) was purchased from R&D systems (Minne-
apolis, MN). Cross-reactive material 197 (CRM197), a
specific inhibitor of HB-EGF, was prepared as described
previously [21]. In the cell viability assay, 20,000–40,000
cells were incubated in RPMI-1640 medium with 5% FBS
and different concentrations of PTX, CDDP, or SN38 on
12-well plates. After a 72-h incubation, the cells were
counted using a hemocytometer after the addition of try-
pan blue exclusion dye to determine the cell viability. In
the apoptosis assay, TUNEL-positive cells were quantified
as apoptotic cells by a flow cytometric analysis as
described previously [22].
DNA extraction, RNA isolation, and cDNA
synthesis
ES-2 cells were suspended in 0.1% SDS/Tris-EDTA buffer
(pH 8.0). After treatment with proteinase K (Sigma-
Aldrich) and RNase A (Invitrogen, Carlsbad, CA), phe-
nol/chloroform extraction and ethanol precipitation were
preformed to purify genomic DNA. Total RNA was iso-
lated using TRIzol reagent (Invitrogen) according to the
manufacturer’s protocol. First-strand cDNA synthesis was
performed with 1 lg of total RNA using with Primescript
II reverse transcriptase (Takara Bio, Otsu, Shiga, Japan)
following the manufacturer’s protocol.
Real-time quantitative PCR (qPCR)
qPCR was performed using TaqMan Universal PCR
Master Mix (Applied Biosystems, Foster City, CA) and
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the samples were analyzed by an Applied Biosystems
7500 Fast Real-time PCR system. TaqMan probes
used were as follow: HB-EGF: Hs00181813_m1; AREG:
Hs00950 669_m1; and GAPDH: Hs02758991_g1. The
methods used for the data analysis were described previ-
ously [12].
Western blot analysis
Whole cell lysates (5 lg) were electrophoresed
through 10% SDS-PAGE gels and proteins were
transferred to a polyvinylidene difluoride membrane
using a semi-dry electroblot (Bio-Rad, Hercules, CA).
The blot was probed with primary antibodies (anti-
human SP1 antibody [#07-645; Millipore, Billerica,
MA], anti-human GAPDH antibody [#ABS16; Milli-
pore]) and secondary antibody (anti-rabbit IgG-Peroxi-
dase [A9169; Sigma-Aldrich]), and then the binding to
antibody was detected using ECL Western Blotting
Detection Regents (General Electric Company, Fairfield,
CT) and a Fuji image analyzer (LAS mini-3000; Fuji-
film, Tokyo, Japan) according to the manufacturer’s
protocol.
ELISA
Cells were incubated with culture medium for 24 h.
After a 24-h incubation, the concentrations of HB-EGF
and AREG in the culture medium were determined
using a commercially available sandwich ELISA (DuoSet
kit; R&D Systems) according to the manufacturer’s
instructions.
Vectors
To generate promoter constructs for the HB-EGF gene
promoter, which were located at !4138 to +205 base pair
(bp), !125 to +205 bp, !178 to +205 bp, and !253 to
+205 bp from its transcriptional start site (TSS), the
sequences were amplified and cloned into pGL4.12 (Pro-
mega, Madison, WI). All nucleotide numbering was done
with reference to the TSS. The primers used for these
PCR assays are listed in Table S1. The pGL4.12 and frag-
ments were digested with KpnI and NcoI restriction
enzymes and ligated. To create pGL/HB!2585/+205 and
pGL/HB!454/+205, pGL/HB!4138/+205 was digested with
NdeI and KpnI or AseI and KpnI, and self-ligation was
performed after blunt-ended treatment with Klenow frag-
ment (Takara Bio). Site-detected mutants of the reporter
vector were constructed by inverse PCR with primers
described in Table S1. The sequences of all generated
vectors were confirmed by DNA sequencing. The
expression vectors for SP1 (EX-Y2188-Lv105) and EGFP
(EX-EGFP-Lv105) were purchased from GeneCopoeia
(Rockville, MD).
Reporter assay
The luciferase assay was performed with ES-2 cells and
293T cells. A total of 25,000 cells were incubated on 24-
well plates for 16 h, and then were cotransfected with
1 lg of promoter reporter vector and 25 ng of pRL-TK
(Promega), which had a renilla-luciferase gene
downstream of the thymidine kinase promoter.
Lipofectamine 2000 (Invitrogen) and Opti-MEM (Gibco)
were used for transfection. When cells were treated with
SN38, the culture medium was changed to RPMI-1640
medium supplemented with 10% FBS and SN38
(10 nmol/L). After a 48-h incubation, Dual-Luciferase
Reporter Assay (Promega) was performed according to
the manufacturer’s protocol.
Small interfering RNA
Stealth RNAi (Invitrogen) against SP1 (siSP1_1: 50-CA
AUGGCAGUGAGUCUUCCAAGAAU-30, siSP1_2: 50-
GACAGGUCAGUUGGCAGACUCUACA-30) and control
siRNAs (Control_1: Stealth RNAi siRNA Negative Con-
trol Lo GC, Control_2: Stealth RNAi siRNA Negative
Control Med GC, Invitrogen) were transfected using
Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s protocol.
Chromatin immunoprecipitation assay
ES-2 cells which were cultured until subconfluent in five
15 cm dishes were fixed in 1% formaldehyde for 10 min
at 37°C. Chromatin was sheared using a Digital Sonifier
S-250D (Branson, Danbury, CT) to yield DNA fragments
of 300–800 bp. Nuclear extraction, immunoprecipitation,
reverse cross-linking, and DNA purification were per-
formed using Magna ChIP A kit (Millipore) according to
the manufacturer’s protocol. An anti-SP1 antibody (#07-
645; Millipore), tri-methyl-histone H3 (Lys4) monoclonal
antibody (#9751S; Cell Signaling Technology, Boston,
MA), and normal rabbit IgG (#2729S; Cell Signaling
Technology) were used in the immunoprecipitation reac-
tions. Quantitative real-time PCR was performed using
SYBR Premix Ex Taq GC (Takara Bio) to detect the
HB-EGF promoter fragments.
Statistical analysis
The two-tailed independent Student’s t-test was used to
calculate all P-values. P < 0.05 was considered statistically
significant.
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Results
Promotion of HB-EGF expression in response
to SN38 treatment
First, we examined the expression of HB-EGF and AREG
in 11 cell lines of OCCC. HB-EGF was highly expressed
in all of the cell lines, and eight of the 11 cell lines had a
high-expression level of AREG (Fig. 1). OVTOKO and
ES-2 cells had the highest expression of HB-EGF, while
the OVISE and RMG-II cells had higher expression of
AREG compared to that of HB-EGF.
To evaluate in vitro anticancer effects of conventional
anticancer agents in the OVISE, RMG-II, OVTOKO, and
ES-2 cells, cell viability assays were performed using SN38
(Fig. 2A), PTX (Fig. 2B), or CDDP (Fig. 2C). In this
analysis, SN38 was a most effective anticancer agent in all
four OCCC cell lines. Real-time PCR showed a twofold
or higher increase in HB-EGF expression induced by the
treatment of the OCCC cells with SN38, and the concen-
tration of HB-EGF also increased more than twofold in
the culture medium of RMG-II and ES-2 cells following
SN38 treatment (Fig. 3A and B). In contrast, a high con-
centration of PTX or CDDP did not induce HB-EGF
expression in ES-2 cells (Fig. 3C). The addition of the
recombinant HB-EGF in cell culture blocked a decrease
in cell viability with the treatment of SN38 in OCCC cells
(Fig. 3D and E). These results indicated that HB-EGF
plays a pivotal role in defense mechanism against the
treatment of SN38 in OCCC cells.
To address the potential synergistic anticancer effects of
the combination of SN38 and a specific inhibitor of HB-
EGF (CRM197), apoptosis assays were performed after
treating ES-2 or OVTOKO cells with SN38 and/or
CRM197. Treatment with 10 lg/mL of CRM197 and
10 nmol/L of SN38 induced a marked increase in the num-
ber of apoptotic ES-2 and OVTOKO cells, compared to
Figure 1. The expression of HB-EGF in 11 ovarian clear cell
carcinoma (OCCC) cell lines. The real-time PCR data show the
expression of heparin-binding epidermal growth factor-like growth
factor (HB-EGF) and amphiregulin (AREG) in OCCC cells. Each value
represents the mean (n = 3) and standard deviation (SD) of the mRNA
expression index for HB-EGF (diagonal striped bars) and AREG (open
bars).
(A)
(C)
(B)
Figure 2. The efficacy of conventional anticancer agents against OCCC cells. Differences in the viability of OVISE (closed squares), RMG-II (closed
circles), OVTOKO (open squares), and ES-2 (open circles) OCCC cells after treatment with SN38 (A), paclitaxel (PTX; B), and cisplatin (CDDP; C) for
72 h. Each value represents the mean cell viability rate (n = 3) and the SD. OCCC, ovarian clear cell carcinoma.
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cells with SN38 treatment alone, as determined using TUN-
EL assay (Fig. 3F and G). These results suggested that the
suppression of HB-EGF during the treatment with SN38
leads to a synergistic anticancer effect in OCCC cells.
Screening for transcription factors that
regulate the HB-EGF expression induced by
SN38 treatment
To identify transcription factor(s) that contribute to the
HB-EGF induction following treatment with SN38, a
promoter analysis was performed using the ES-2 cells. For
the reporter gene analysis, a HB-EGF promoter fragment
(!2585/+205), which is conserved among mammalian
species, fused to a luciferase vector, and various truncated
constructs were synthesized. The luciferase assay showed
that a reporter vector containing promoter fragment of
!178/+205 bp from HB-EGF TSS (pGL/HB!178/+205)
exhibited an about 20-fold increase in luciferase activity
compared to that of pGL/HB!125/+205 (Fig. 4A). Addi-
tionally, treatment with SN38 induced ~twofold increase
in the luciferase activity in a reporter vector containing
(A) (B)
(C)
(E) (F) (G)
(D)
Figure 3. The association between HB-EGF expression and the SN38 treatment of OCCC cells. The induction of HB-EGF mRNA in cells (A) and
HB-EGF protein in the culture medium (B) in OVTOKO (open bars), OVISE (diagonal striped bars), RMG-II (gray bars), and ES-2 (closed bars) cells
treated with SN38 (10 nmol/L) for 12 or 24 h. Each value represents the mean (n = 3) and SD. (C) The differences in the HB-EGF mRNA
expression in ES-2 cells after the treatment with SN38 (open bars), CDDP (diagonal striped bars), or PTX (gray bars). The differences in cell
viabilities of RMG-II (D) and OVISE (E), which were cultured with recombinant human HB-EGF (0 and 200 pg/mL) and SN38 (0, 50, and 100 nmol/
L). Each value represents the mean fold change (n = 3) and the SD. *P < 0.05. The changes in the apoptosis rate of ES-2 (F) and OVTOKO (G)
cells after the treatment with each concentration of SN38 with (closed bars) or without CRM197 (10 lg/mL, diagonal striped bars). Each value
represents the mean apoptosis ratio (n = 3) and SD. *P < 0.05, SN38-only versus SN38 with CRM197. HB-EGF, heparin-binding epidermal growth
factor-like growth factor; PTX, paclitaxel.
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pGL/HB!178/+205 compared to the control (Fig. 4A).
Accordingly, the sequence located !178 to !125 bp from
the TSS of HB-EGF was recognized as a promoter
sequence bound by transcription factors.
Using the MatInspector (http://www.genomatix.de) and
AliBaba 2.1 (http://www.gene-regulation.com) in silico
analysis programs, we found that SP1-binding sites are
commonly found in this promoter sequence (Fig. 4B).
Since the HB-EGF promoter has a TATA-less and GC-
rich promoter, which are characteristics of SP1-binding
promoters, we focused on SP1 as the candidate transcrip-
tion factor inducing HB-EGF in SN38-treated ES-2 cells
[17, 23, 24].
Reporter vectors with site mutations of each SP1-bind-
ing site showed significantly reduced luciferase activity
compared to the control (Fig. 4C). Moreover, the lucifer-
ase activity significantly decreased, compared to the con-
trol, when the two putative binding sites of SP1 were
replaced with mutant sites (Fig. 4C). Forced expression of
SP1 activated the luciferase activity in 298T cells transfect-
ed with pGL/HB!178/+205, although no difference was
found between the forced expression of SP1 and control
in 293T cells transfected by pGL/HB!125/+205 (Fig. 4D).
To detect direct interaction between the SP1 protein
and HB-EGF promoter in ES-2 cells, a chromatin immu-
noprecipitation assay was performed in cells with or with-
out treatment with SN38. Quantitative real-time PCR
showed that, during treatment with SN38, the level of
HB-EGF promoter bound to SP1 significantly increased
compared to that of control cells (Fig. 4E). These results
indicated that the HB-EGF expression promoted by the
treatment with SN38 was regulated by SP1 in OCCC
cells.
Contribution of SP1 to the HB-EGF
expression and SN38 sensitivity of OCCC
cells
To confirm whether SP1 affects the sensitivity of cells
to SN38 via the induction of HB-EGF expression, the
expression and the cell viability assays were performed
after the transfection of small interfering RNA (siRNA)
targeting SP1. A Western blot analysis showed that the
ES-2 cells transfected with siSP1_1 and siSP1_2 had
reduced expression of the SP1 protein compared to the
cells transfected with control siRNAs (Fig. 5A). In the
ES-2 cells transfected with siSP1_2, the HB-EGF expres-
sion was reduced to approximately half the control
level, although the HB-EGF expression was not altered
in the ES-2 cells transfected with siSP1_1 (Fig. 5B). No
induction of HB-EGF expression was found in the pres-
ence of SN38 in the ES-2 cells transfected with either
siSP1_1 or siSP1_2 (Fig. 5C). Additionally, we examined
alterations in the cell viabilities using RMG-II cells,
which had the least antitumor effect with the treatment
of SN38. Following the treatment with SN38, the num-
ber of RMG-II cells transfected with siSP1_1 and
siSP1_2 significantly decreased compared to that in the
RMG-II cells transfected with control siRNAs (Fig. 6).
These results indicate that SP1 regulates the drug sensi-
tivity of SN38 by regulating the HB-EGF expression in
OCCC cells.
Discussion
In this study, HB-EGF was attributable for the escape
from cell death, as SN38 damaged OCCC cells. SP1 acti-
vated HB-EGF expression through its binding to multiple
transcription sites within the promoter of HB-EGF in
OCCC cells. In addition, the suppression of HB-EGF as
well as SP1 enhanced the sensitivity of SN38 in OCCC
cells.
SP1, which belongs to the family of SP1/Kruppel-like
factor (KFL) transcriptional factors, regulates the expres-
sion of numerous genes involved in cell proliferation,
apoptosis, and differentiation [25]. Phorbol 12-myristate
13 acetate (PMA) induced an increase in the transcrip-
tional activity of SP1 through the deacetylation of SP1,
and also provoked the ectodomain shedding of HB-EGF;
it also increased the expression of HB-EGF [26, 27].
Figure 4. The interaction of SP1 with the HB-EGF promoter region following SN38 treatment. (A) The alterations in the luminescence of ES-2
cells for each reporter vector in cells with (open bars) and without (diagonal striped bars) SN38 (10 nmol/L) treatment. A schematic diagram
showing the reporter vectors on the left side. (B) A schematic diagram obtained from the in silico analysis including the MatInspector and AliBaba
2.1 programs. (C) The luciferase reporter analysis of the site mutants in ES-2 cells. The schematic diagram shows the wild-type SP1-binding sites
as “SP1” and the mutated binding sites as “mu” in each vector. The alterations in the luminescence of ES-2 cells among the wild-type reporter
vector (open bar) and the mutated reporter vectors (diagonal striped bars) in the presence of SN38 (10 nmol/L). Each value represents the mean
(n = 3) and SD. (D) The differences in the relative luciferase activity of 293T cells transfected with pGL/HB!178/+205 and the SP1 expression vector
(diagonal striped bars). An EGFP expression vector was used as a control (gray bars). Each value represents the mean (n = 3) and SD. All relative
luciferase activities were normalized to the renilla luminescence. (E) The results of the ChIP analysis of ES-2 cells with or without SN38 (10 nmol/L)
treatment. The fold change in the immunoprecipitated DNA for SP1 (open bars) against templates due to the nonspecific binding with IgG (gray
bars). Each value represents the mean (n = 3) and SD. *P < 0.05, versus control. HB-EGF, heparin-binding epidermal growth factor-like growth
factor; SP1, specific protein 1.
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Additionally, NF-jB induced the expression of HB-EGF,
and the NF-jB and SP1 binding sequence was shown to
be the same GC-rich element in colon cancer cells [16,
28]. This evidence suggests that SP1 augments the expres-
sion of HB-EGF through the deacetylation of SP1 or via
an interaction with NF-jB. In mice, SP1 was reported to
be directly bound to the promoter regions of HB-EGF
[24]. In humans, SP1 also functions as a direct regulator
for the expression of HB-EGF, possibly through various
posttranslational modifications of SP1 and by interactions
with other transcriptional factors.
Dysregulation of SP1 is found in many types of cancer,
including ovarian, breast, and gastric cancer, for which
HB-EGF is a rational therapeutic target [22, 29, 30]. The
hypoxia-inducible factor 2a (HIF2a)–SP1 complex acti-
vated coagulation factor VII promoter in OCCC and
estrogen receptor a also form complexes with SP1 in
other types of ovarian cancer [31, 32]. Additionally, pre-
vious reports showed that activation of SP1 promoted
breast cancer development and the metastasis of gastric
cancer [33, 34]. On the other hand, the SP1 level was
highly upregulated in patients with early stage and mini-
mally invasive lung cancer cells and in patients with stage
I lung cancer compared to that in lung cancers with high
invasiveness and in patients with stage IV lung cancer
[35]. These previous findings show that the significance
of SP1 involvement in cancer progression have been con-
troversial. In this study, the suppression of SP1 enhanced
the sensitivity of OCCC cells to SN38. Therefore, it seems
to be important that the suppression of SP1 itself, as well
as the inhibition of the posttranslational modifications of
SP1, are critical for cancer therapy.
Several compounds that inhibit the transcriptional
activity of SP1 have been developed for cancer therapy
[25], for example, arsenic trioxide downregulates the
expression of SP1 [36]. A phase III trial of arsenic triox-
ide was performed for patients with acute promyelocytic
leukemia classified as having low-to-intermediate risk,
and the results suggested that all-trans-retinoic acid plus
arsenic trioxide may be superior to all-trans-retinoic acid
(A)
(C)
(B)
Figure 5. The contribution of SP1 to the HB-EGF induction following
the treatment with SN38. (A) A Western blot analysis was performed
to confirm the SP1 reduction in the transfected ES-2 cells induced by
treatment with siRNAs against SP1 or a control siRNA. (B) The
alterations in the HB-EGF mRNA expression in the transfected ES-2
cells induced by treatment with the siRNAs against SP1 or the control
siRNA. (C) The induction of HB-EGF mRNA in the RMG-II cells
transfected with siRNAs against SP1 or the control siRNA following
the treatment of SN38. Each value represents the mean (n = 3) and
SD. Closed bars, control_1 siRNA; gray bars, control_2 siRNA;
diagonal striped bars, siSP1_1 si RNA; open bars, siSP1_2 siRNA.
*P < 0.05, control_1 versus each siRNA. SP1, specific protein 1.
Figure 6. The contribution of SP1 to the cell viabilities following the
treatment with SN38. The alterations in the numbers of RMG-II cells
transfected with siRNAs against SP1 or a control siRNA after
treatment with SN38. Each value represents the mean (n = 3) and SD.
Closed bars, control_1 siRNA; gray bars, control_2 siRNA; diagonal
striped bars, siSP1_1 si RNA; open bars, siSP1_2 siRNA. *P < 0.05,
control_1 versus each siRNA. SP1, specific protein 1.
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plus other chemotherapy [37]. Bortezomib has been
already used for the treatment of patients with multiple
myeloma [38, 39]. Bortezomib has been shown to
decrease the expression of SP1 and disrupt the interaction
of SP1 with NF-jB [40]. Other inhibitory compounds for
SP1 will be clinically applied for various diseases, in addi-
tion to cancer [41, 42].
We have performed a clinical phase II trial using
CRM197 in patients with recurrent and advanced ovarian
cancer. To explore the importance of the posttranslational
modifications of SP1 in the induction of HB-EGF expres-
sion and to search for compounds that can inhibit such
modifications, a preclinical study should be performed
using combination therapy with CRM197, irinotecan, and
a compound that inhibits SP1, such as arsenic trioxide or
bortezomib. Such a combination would likely improve
the prognosis of patients with OCCC.
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Primer        Sequence 
forward primer for the HB-EGF reporter vector   GCCCATGGTCCCGCACCGAGAGG  
reverse primer for pGL/HB-4138/+205    GCGGTACCAATGAGAAGGCAGCTGAA  
reverse primer for pGL/HB-125/+205    GCGGTACCGCTGCCGGCGCCGCGAGCCG 
reverse primer for pGL/HB-178/+205    GCGGTACCCGCCGCCCTCTCCTCCC  
reverse primer for pGL/HB-253/+205    GCGGTACCTCCGCCACCTGCCGGTC  
forward primer for pGL/HB mu1     aataGCCCGCGGGGTCGGGGGCTG  
reverse primer for pGL/HB mu1     CGGAGGACTGGGCGGGAGGAGAGGG 
forward primer for pGL/HB mu2     ataCCGCGGGGTCGGGGGCTG  
reverse primer for pGL/HB mu2     CGGCGGAGGACTGGGCGGGAGGAGA 
forward primer for ChIP PCR     TCCCGTGCTGGGAAGCTCGC  
reverse primer for ChIP PCR     TGCCTCGGCCTGGTCCCAAAA  
Table S1.  Primer sequences 
